➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Express Scripts
Harvard Business School
Moodys

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

KYNMOBI Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Kynmobi, and what generic alternatives are available?

Kynmobi is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has two hundred and thirty-six patent family members in twenty-four countries.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Kynmobi

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 16, 2031. This may change due to patent challenges or generic licensing.

There have been twenty-nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for KYNMOBI
Drug Prices for KYNMOBI

See drug prices for KYNMOBI

Generic Entry Opportunity Date for KYNMOBI
Generic Entry Date for KYNMOBI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FILM;SUBLINGUAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for KYNMOBI
Drug ClassDopaminergic Agonist
Mechanism of ActionDopamine Agonists

US Patents and Regulatory Information for KYNMOBI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKinsey
Baxter
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.